علاج فرط فوسفات الدم في المرحلة 4 من الفشل الكلوي المزمن

References

• Calcium-based products are often started in stage 4 secondary to efficacy, safety, and cost.
• Approved in 1990, calcium acetate (PhosLo, various other brands) is considered a first-line therapy for lowering phosphate in CKD stage 4.
• Calcium-based phosphate binders are the mainstay of phosphate-lowering therapy in CKD stage 4.
• Overall cost of this medication is low, so it is an attractive first-line agent if hypercalcemia is not a concern.
• In general, the goal is to achieve a phosphorus concentration of 2.7 to 4.6 mg/dL in patients not receiving dialysis.